• Opinion: A consultant wrote the playbook on drug pricing - then distanced himself from it

    3 days ago - By STAT

    When Biogen announced the price for Aduhelm, its controversial Alzheimer's drug, the explanation the company gave - it represented the “overall value this treatment brings to patients, caregivers and society” - came right out of Mick Kolassa's playbook.
    For many years, Kolassa was the man drug companies turned to when they wanted advice on how to price a drug.
    Read more ...